Insider Selling: Glaukos Co. (NYSE:GKOS) Director Sells $288,020.00 in Stock

Glaukos Co. (NYSE:GKOS) Director Gilbert H. Kliman sold 2,000 shares of Glaukos stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $144.01, for a total value of $288,020.00. Following the sale, the director now directly owns 32,336 shares of the company’s stock, valued at approximately $4,656,707.36. This trade represents a 5.82 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Glaukos Trading Down 1.0 %

Shares of NYSE:GKOS opened at $138.93 on Monday. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. The firm has a market capitalization of $7.66 billion, a P/E ratio of -46.00 and a beta of 1.03. The business’s 50-day moving average is $136.25 and its 200 day moving average is $127.05. Glaukos Co. has a 1 year low of $65.00 and a 1 year high of $147.65.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.20. The firm had revenue of $96.70 million during the quarter, compared to analyst estimates of $91.50 million. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. Glaukos’s revenue was up 23.9% on a year-over-year basis. During the same period last year, the firm posted ($0.50) EPS. On average, research analysts predict that Glaukos Co. will post -1.89 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently weighed in on GKOS shares. Stephens upgraded Glaukos to a “strong-buy” rating in a report on Monday, December 2nd. Truist Financial boosted their price target on shares of Glaukos from $145.00 to $152.00 and gave the company a “buy” rating in a report on Monday, October 14th. Stifel Nicolaus increased their price objective on shares of Glaukos from $145.00 to $153.00 and gave the company a “buy” rating in a research note on Monday, December 2nd. BTIG Research boosted their price objective on shares of Glaukos from $140.00 to $149.00 and gave the stock a “buy” rating in a research note on Tuesday, November 26th. Finally, JPMorgan Chase & Co. increased their target price on Glaukos from $130.00 to $145.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. One analyst has rated the stock with a sell rating, two have given a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Glaukos presently has an average rating of “Moderate Buy” and an average price target of $143.17.

Institutional Investors Weigh In On Glaukos

Large investors have recently made changes to their positions in the stock. Cetera Advisors LLC purchased a new position in Glaukos during the 1st quarter worth approximately $213,000. Sequoia Financial Advisors LLC purchased a new position in shares of Glaukos during the second quarter worth $229,000. Assenagon Asset Management S.A. acquired a new position in Glaukos during the second quarter valued at $6,832,000. Raymond James & Associates boosted its holdings in Glaukos by 23.2% in the second quarter. Raymond James & Associates now owns 13,017 shares of the medical instruments supplier’s stock valued at $1,541,000 after purchasing an additional 2,452 shares during the last quarter. Finally, Fifth Third Wealth Advisors LLC acquired a new stake in Glaukos during the 2nd quarter worth about $187,000. 99.04% of the stock is owned by hedge funds and other institutional investors.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.